A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...

Catching pancreatic cancer early can increase the five-year survival rate from 15% to 80%. Patients with pancreatic cysts, ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

An artificial intelligence model from the Mayo Clinic detected early signs of possible pancreatic cancer on scans up to two years before patients were diagnosed.

Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have ...

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic ...

Researchers have uncovered an unexpected weakness in pancreatic cancer involving damaged mitochondria and a powerful ...

LUND, Sweden, Aug. 1, 2024 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the pancreatic cancer diagnostics company, today announces enhanced performance for its next-generation test for ...

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and ...

An AI model developed at the Mayo Clinic in Rochester, Minnesota, detected abnormalities on patients’ CT scans up to three years before they were diagnosed with pancreatic cancer, according to ...